Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis.
about
Bacterial flavohemoglobin: a molecular tool to probe mammalian nitric oxide biologyRegulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolaseInvolvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemiaDimethylarginines in chronic renal failureDimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesisEndothelial nitric oxide in humans in health and disease.Regulation of nitric oxide synthesis in the liver.Asymmetric dimethylarginine does not inhibit arginase activity and is pro-proliferative in pulmonary endothelial cells.Novel therapeutic strategies for adult obese asthmatics.Asymmetric dimethylarginine potentiates lung inflammation in a mouse model of allergic asthma.Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells.The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension.Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.Mechanism of cellular oxidation stress induced by asymmetric dimethylarginine.Effect of interaction between left ventricular dysfunction and endothelial function in hypertension.Competitive metabolism of L-arginine: arginase as a therapeutic target in asthma.Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice.Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertensionA study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuriaMacula densa arginine delivery and uptake in the rat regulates glomerular capillary pressure. Effects of salt intake.Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants.Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.Molecular mechanisms underlying the role of nitric oxide in the cardiovascular system.Endogenously produced nitric oxide inhibits endothelial cell growth as demonstrated using novel antisense cell lines.Regulation of macrophage nitric oxide synthesis by endothelial cells: a role for NG,NG-dimethylarginine.A relative L-arginine deficiency contributes to endothelial dysfunction across the stages of the menopausal transition.Inhibition of nitric oxide synthase by antisense techniques: investigations of the roles of NO produced by murine macrophagesFunctional effects of econazole on inducible nitric oxide synthase: production of a calmodulin-dependent enzyme.Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases?Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice.The inhibitory effect of quercetin on asymmetric dimethylarginine-induced apoptosis is mediated by the endoplasmic reticulum stress pathway in glomerular endothelial cells.Nitric oxide in the human cardiovascular system--SKB lecture 1997.Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro.Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia.ADMA regulates angiogenesis: genetic and metabolic evidence.Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-β1 synthesis.Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients.Temporal effects of low-dose ACE inhibition on endothelial function in Type 1 diabetic patients.
P2860
Q24633608-9C726252-7910-4388-B206-FCE963ECAF91Q24674431-176681E7-39FD-4B64-9645-7814D0E93608Q28363811-79C934F9-432F-4FD4-90DB-E03FA5FA679CQ28365942-6FF612FD-B99D-43C4-912A-945F26DAC3E4Q28578409-A32AF147-932F-4DB7-8C4C-5E5DC31AB636Q33815804-E5D25253-7E35-4C17-B8DC-B84128A6A7DAQ33910539-AA8401BD-B83E-4973-B637-5C6266A853F9Q33934764-D4383982-B22D-4B7F-A311-5CB90BB325FFQ34290008-D0ABDA9C-F803-4B2D-9AA9-22AD8045EB58Q34426054-ADB52D51-AD39-4CB8-B8FA-D7BC6CF597F8Q35035933-DA98E44B-0BAF-42CF-9D08-92C9E6651099Q35120875-63C3928D-7EED-428C-9AB2-95D7F1FF512FQ36018553-217F94E1-8324-4AD5-83FB-D89A8EF85C35Q36097000-750D0560-B8F4-4D59-B1F1-E078779AED79Q36674335-AFC6DDBE-259B-4176-96E5-538F4A57DD2DQ36682074-78C0E569-BEC1-443B-90E4-87E5A85F1A69Q36861289-6C45A624-4256-412A-91DE-815C5F882AE9Q36997972-4575FB90-77EC-417E-8914-0DECCCDB26BDQ37078022-A13EE64F-BABE-4569-BA7D-53C67179ED2DQ37100474-950ECB11-D03C-4CCC-9B59-75CF6701C5EBQ37233690-C336D94A-B6CE-45F7-A119-78090272FAA4Q37374250-87A9433B-4216-4CE9-B10E-A02FED6E3542Q38468092-9B81085A-F254-4E58-AEE8-452942C9C4D8Q40380245-6228E446-2C2D-4FDE-9241-7B00F829A15CQ40409036-ED069596-4CA9-46FE-9E0F-F253CFDAD160Q40858861-812A3929-1024-40A3-9819-DD156D63E06CQ40916402-D0F898F5-D7BD-41BE-8B8E-2ECD085AD3C5Q41037479-82284CB0-D529-4962-AE6E-1D7040615627Q41140097-63699884-4F7B-447C-AB56-3EC6FFBD0E41Q41219811-234777C8-0F7F-4A2E-9CC6-A3BFFFA540CEQ41304976-F57E2069-CE70-49FD-91A5-306B15B36679Q41731426-8D69A45E-20BE-481C-AE21-9C5FA826F1A3Q41869460-450F969B-752B-4ED4-83ED-316D9C771B41Q42009952-E1D97EE6-C00B-4991-853F-32253B87C32CQ42113933-243000CE-C047-4309-BC0B-550E8628ED50Q43993565-3AF5C416-885D-489F-9BFF-B1E7D459C73EQ46127047-6A2FE3EC-1138-4D50-A89F-DFD733D15714Q46214258-BF8BDABC-9057-4D26-A552-E8DFFDB5C03BQ46367547-E4EDE63A-3EBA-46C3-920E-9C84CC71D2C6Q46907016-78200B18-9566-42FF-B178-3AFEDA4E90EE
P2860
Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Metabolism of methylarginines ...... ion of nitric oxide synthesis.
@en
type
label
Metabolism of methylarginines ...... ion of nitric oxide synthesis.
@en
prefLabel
Metabolism of methylarginines ...... ion of nitric oxide synthesis.
@en
P2093
P2860
P1476
Metabolism of methylarginines ...... ion of nitric oxide synthesis.
@en
P2093
G S Whitley
P Vallance
R J MacAllister
S A Fickling
P2860
P356
10.1111/J.1476-5381.1994.TB13026.X
P407
P577
1994-05-01T00:00:00Z